In vitro and in vivo RRx-001 synergy with regorafenib and in vivo attenuation of regorafenib-induced toxicity

被引：0
|
作者：
Oronsky, Bryan [1 ]
Reid, Tony [1 ]
Carter, Corey [1 ]
Cabrales, Pedro [2 ]
Larson, Christopher
机构：
[1] EpicentRx Inc, La Jolla, CA USA
[2] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P502
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenografts
    Reid, Tony
    Oronsky, Bryan
    Abrouk, Nacer
    Caroen, Scott
    Cabrales, Pedro
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (04): : 1912 - 1918
  • [2] Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma
    Cheng, Mengting
    Tao, Xinyu
    Wang, Fei
    Shen, Nonger
    Xu, Zhifei
    Hu, Yuhuai
    Huang, Ping
    Luo, Peihua
    He, Qiaojun
    Zhang, Yiwen
    Yan, Fangjie
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (09) : 907 - 922
  • [3] Targeting Regorafenib-Induced Toxicity through Inhibition of Gut Microbial β-Glucuronidases
    Ervin, Samantha M.
    Hanley, Ronan P.
    Lim, Lauren
    Walton, William G.
    Pearce, Kenneth H.
    Bhatt, Aadra P.
    James, Lindsey I.
    Redinbo, Matthew R.
    ACS CHEMICAL BIOLOGY, 2019, 14 (12) : 2737 - 2744
  • [4] Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo
    Pan, Po-Jung
    Liu, Yu-Chang
    Hsu, Fei-Ting
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [5] Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer
    Bajpai, Prachi
    Agarwal, Sumit
    Afaq, Farrukh
    Al Diffalha, Sameer
    Chandrashekar, Darshan S.
    Kim, Hyung-Gyoon
    Shelton, Abigail
    Miller, C. Ryan
    Singh, Santosh K.
    Singh, Rajesh
    Varambally, Sooryanarayana
    Nagaraju, Ganji Purnachandra
    Manne, Ashish
    Paluri, Ravi
    Khushman, Moh'd
    Manne, Upender
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [6] A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo
    Mayer, Barbara
    Karakhanova, Svetlana
    Bauer, Nathalie
    Liu, Li
    Zhu, Yifan
    Philippov, Pavel P.
    Werner, Jens
    Bazhin, Alexandr V.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2017, 390 (11) : 1125 - 1134
  • [7] A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo
    Barbara Mayer
    Svetlana Karakhanova
    Nathalie Bauer
    Li Liu
    Yifan Zhu
    Pavel P. Philippov
    Jens Werner
    Alexandr V. Bazhin
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390 : 1125 - 1134
  • [8] Regorafenib (Stivarga®) reverses BCRP-mediated multidrug resistance in vitro and in vivo
    Zhang, Yun-Kai
    Wang, Yi-Jun
    Zhang, Guan-Nan
    Zhang, Wen-Ji
    Wei, Meng-Ning
    Shi, Zhi
    Chen, Zhe-Sheng
    CANCER RESEARCH, 2017, 77
  • [9] Development and evaluation of regorafenib loaded liquid suppository for rectal delivery: In vitro, in vivo analyses
    Saleem, Aiman
    Din, Fakhar ud
    Ali, Zakir
    Zahid, Fatima
    Alamri, Ali H.
    Lahiq, Ahmed A.
    Alqahtani, Taha
    Alharbi, Hanan M.
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024, 91
  • [10] In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).
    Serrano-Garcia, Cesar
    Heinrich, Michael C.
    Zhu, Meijun
    Raut, Chandrajit P.
    Eilers, Grant
    Ravegnini, Gloria
    Demetri, George D.
    Bauer, Sebastian
    Fletcher, Jonathan A.
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345